Skip to main
ICCM
ICCM logo

ICCM Stock Forecast & Price Target

ICCM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Icecure Medical Ltd is positioned for a positive growth trajectory, with anticipated topline sales improvement expected in the first half of 2026, supported by potential FDA marketing authorization for their ProSense cryoablation system aimed at breast cancer by 2025. The successful De Novo clearance aligns with expectations and highlights the effectiveness of Icecure's liquid nitrogen-based cryoablation technology as a minimally invasive treatment for low-risk, early-stage breast cancer. Additionally, a narrower net loss of $3.6 million, compared to an expected $4.4 million, reflects improved operational efficiency, bolstering confidence in the company's financial health moving forward.

Bears say

IceCure Medical Ltd reported a revenue of $725K for 1Q25, reflecting a 2% decline year-over-year, primarily driven by decreased sales in Asia despite growth in Europe and North America. There are substantial concerns regarding the commercial viability of its cryoablation systems, with risks including potential failure to achieve market success due to competition, market size limitations, and penetration rates. Additionally, the company faces dilution risks and challenges related to securing regulatory approval in the U.S., further contributing to a negative outlook on its stock.

ICCM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Icecure Medical Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Icecure Medical Ltd (ICCM) Forecast

Analysts have given ICCM a Strong Buy based on their latest research and market trends.

According to 1 analysts, ICCM has a Strong Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Icecure Medical Ltd (ICCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.